An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.
<h4>Background</h4>The transmembrane receptor tyrosine kinase HER2 is overexpressed in approximately 15% of breast tumors and correlates with poor clinical prognosis. Several treatments that target HER2 are approved for treatment of HER2-positive metastatic breast cancer. The serum bioma...
| Main Authors: | , , , , , , , , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
Public Library of Science (PLoS)
2020-01-01
|
| 丛编: | PLoS ONE |
| 在线阅读: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0227356&type=printable |